Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
This new indication also applies to Kisqali Femara Co-Pack (ribociclib with letrozole). The approval was based on data from the phase 3 NATALEE trial (NCT03701334), which enrolled 5101 adults with ...
The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...
Regulatory reviews for ribociclib among patients with early breast cancer are continuously ongoing to include the EMA and China. 1. FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara ...
In addition to this approval, the FDA also approved the ribociclib and letrozole co-pack for the same indication. 1 2. FDA ...